Clinical Considerations for PSMA PET Agents in Advanced Prostate Cancer

This episode, titled ‘Clinical Considerations for PSMA PET Agents in Advanced Prostate Cancer,’ the expert faculty review the currently FDA-approved PSMA PET diagnostic agents and their labeled indications, which are largely similar and include initial staging, biochemical recurrence, and evaluation for radioligand therapy. Clinicians note that while the molecular differences among agents exist, proper ordering, interpretation, and clinical context are often more important than subtle structural variations. Common physiologic uptake patterns—such as in the bladder, kidneys, liver, pancreas, and salivary glands—are discussed to help distinguish expected agents distribution from suspicious findings. The conversation also explores potential differences in urinary excretion among agents, highlighting data from a phase 4 study suggesting lower bladder activity with one of these agents. These differences may have practical implications in post-prostatectomy patients, where urinary activity can obscure evaluation of the prostate bed and influence diagnostic confidence.

In the next episode, ‘Clinical Reliability of PSMA PET in Advanced Prostate Cancer,’ panelists highlight the high specificity and clinical utility of PSMA PET imaging in assessing tumor burden, while acknowledging its limitations in detecting microscopic disease. Growing confidence in its performance is influencing earlier imaging decisions and shaping management in biochemical recurrence and advanced prostate cancer.